Your browser is no longer supported. Please, upgrade your browser.
Settings
AGEN [NASD]
Agenus Inc.
Index- P/E- EPS (ttm)-0.11 Insider Own0.50% Shs Outstand235.41M Perf Week-6.80%
Market Cap829.93M Forward P/E- EPS next Y-0.90 Insider Trans-6.61% Shs Float226.93M Perf Month-17.97%
Income3.80M PEG- EPS next Q-0.27 Inst Own47.90% Short Float6.73% Perf Quarter-48.95%
Sales306.70M P/S2.71 EPS this Y-31.40% Inst Trans4.53% Short Ratio3.65 Perf Half Y-22.60%
Book/sh0.18 P/B17.50 EPS next Y-246.40% ROA1.40% Target Price9.00 Perf Year-14.86%
Cash/sh0.99 P/C3.17 EPS next 5Y- ROE-2.50% 52W Range2.50 - 6.79 Perf YTD-0.94%
Dividend- P/FCF- EPS past 5Y1.40% ROI- 52W High-53.61% Beta1.09
Dividend %- Quick Ratio2.10 Sales past 5Y28.90% Gross Margin98.90% 52W Low26.00% ATR0.27
Employees359 Current Ratio2.10 Sales Q/Q-60.20% Oper. Margin21.00% RSI (14)24.97 Volatility5.64% 7.02%
OptionableYes Debt/Eq0.32 EPS Q/Q358.10% Profit Margin1.20% Rel Volume1.31 Prev Close3.15
ShortableYes LT Debt/Eq0.31 EarningsNov 09 BMO Payout- Avg Volume4.18M Price3.15
Recom1.30 SMA20-18.30% SMA50-32.29% SMA200-30.15% Volume5,488,722 Change0.00%
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Dec-16-15Initiated Jefferies Buy
Oct-27-15Downgrade Maxim Group Buy → Hold
Jul-27-15Reiterated MLV & Co Buy $9 → $11
Jun-11-15Initiated Oppenheimer Outperform $14
Jan-12-15Reiterated Maxim Group Buy $10 → $11
Jan-09-15Reiterated MLV & Co Buy $6 → $9
Jan-09-15Reiterated Maxim Group Buy $10 → $11
Dec-19-14Reiterated Maxim Group Buy $8 → $10
May-08-14Reiterated Maxim Group Buy $17 → $11
Mar-14-14Reiterated MLV & Co Buy $9 → $11
Oct-08-13Reiterated Maxim Group Buy $19
Jan-05-12Initiated William Blair Outperform
Dec-01-11Initiated Global Hunter Securities Buy $6
Nov-18-21 10:00AM  
Nov-17-21 08:30AM  
Nov-12-21 07:30PM  
01:04PM  
07:00AM  
Nov-10-21 09:32AM  
Nov-09-21 04:21PM  
09:25AM  
08:00AM  
08:00AM  
Nov-05-21 10:56AM  
Nov-04-21 08:30AM  
Nov-02-21 03:01PM  
Oct-26-21 10:00AM  
Oct-25-21 08:30AM  
Oct-24-21 10:00AM  
Oct-22-21 12:48PM  
12:22PM  
08:00AM  
Oct-13-21 02:39PM  
Oct-12-21 08:30AM  
05:52AM  
Oct-01-21 08:00AM  
Sep-17-21 06:35AM  
Sep-16-21 06:25PM  
Sep-10-21 07:30AM  
Sep-09-21 08:00AM  
Aug-26-21 09:00AM  
Aug-15-21 03:00AM  
Aug-09-21 07:07PM  
04:00PM  
09:05AM  
07:45AM  
Aug-02-21 04:05PM  
03:01PM  
Jul-28-21 08:30AM  
Jul-27-21 06:21PM  
Jul-26-21 04:05PM  
08:50AM  
Jul-20-21 07:40AM  
Jul-07-21 04:05PM  
Jul-06-21 09:20AM  
08:30AM  
06:27AM  
Jul-05-21 08:50AM  
Jun-30-21 01:06AM  
Jun-21-21 09:00AM  
Jun-17-21 01:01PM  
08:30AM  
Jun-15-21 08:30AM  
Jun-08-21 11:45AM  
Jun-04-21 09:09AM  
Jun-01-21 04:05PM  
May-23-21 06:43AM  
May-20-21 07:00AM  
May-19-21 05:06PM  
04:32PM  
10:38AM  
10:00AM  
09:38AM  
08:46AM  
May-18-21 04:20PM  
09:16AM  
08:26AM  
08:14AM  
07:31AM  
07:30AM  
May-06-21 03:55PM  
03:30PM  
08:55AM  
07:45AM  
06:45AM  
Apr-28-21 05:30PM  
Apr-22-21 04:05PM  
Apr-19-21 08:30AM  
Apr-14-21 08:30AM  
Apr-10-21 08:35AM  
Apr-06-21 08:30AM  
Mar-15-21 04:00PM  
09:05AM  
08:25AM  
07:45AM  
06:30AM  
Mar-10-21 04:33PM  
Mar-08-21 12:30PM  
Mar-02-21 08:30AM  
Feb-09-21 05:06PM  
11:00AM  
08:45AM  
Feb-05-21 07:43AM  
Feb-04-21 08:30AM  
Jan-31-21 01:00AM  
Jan-26-21 08:30AM  
Jan-19-21 12:09PM  
Dec-13-20 09:44PM  
Dec-03-20 07:45AM  
Dec-01-20 08:00AM  
Nov-25-20 01:28PM  
Nov-16-20 07:04PM  
Nov-13-20 02:43PM  
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AGENUS INC10% OwnerOct 19Buy12.001,400,00016,800,00020,881,000Oct 20 07:37 PM
ARMEN GARO HChairman and CEOSep 13Option Exercise3.36119,178400,438852,880Sep 14 05:30 PM
ARMEN GARO HChairman and CEOSep 13Sale6.5082,107533,696770,773Sep 14 05:30 PM
KLASKIN CHRISTINE MPFO & PAOSep 10Option Exercise3.3616,56355,652104,176Sep 14 05:30 PM
KLASKIN CHRISTINE MPFO & PAOSep 10Sale6.5011,12072,28093,056Sep 14 05:30 PM